青城新药-B(02396)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02396 青城新药-B

已收盘 10-20 15:55:03

3.850

+0.020

+0.52%

最高4.090	最低3.750	成交量3.68万
今开3.815	昨收3.830	日振幅8.88%
总市值4.53亿	流通市值3.20亿	总股本1.18亿
成交额14.11万	换手率0.04%	流通股本8,302万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02396","market":"HK","secType":"STK","nameCN":"青城新药-B","latestPrice":3.85,"timestamp":1792482903820,"preClose":3.83,"halted":0,"volume":36800,"delay":0,"changeRate":0.005221932114882511,"floatShares":83022145,"shares":117657522,"eps":-2.08,"marketStatus":"已收盘","change":0.02,"latestTime":"10-20 15:55:03","open":3.815,"high":4.09,"low":3.75,"amount":141144,"amplitude":0.088773,"askPrice":3.8,"askSize":2400,"bidPrice":3.68,"bidSize":1200,"shortable":0,"etf":0,"ttmEps":-2.39,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792546200000},"marketStatusCode":5,"adr":0,"listingDate":1766332800000,"exchange":"SEHK","adjPreClose":3.83,"openAndCloseTimeList":[[1792459800000,1792468800000],[1792472400000,1792483200000]],"volumeRatio":2.839506,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02396","defaultTab":"news","newsList":[{"id":"1187717222","title":"青城新药-B（02396）委任贾丽加兼任首席执行官并公布过户暂停安排","url":"https://stock-news.laohu8.com/highlight/detail?id=1187717222","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187717222?lang=zh_cn&edition=full","pubTime":"2026-10-20 20:55","pubTimestamp":1792500934,"startTime":"0","endTime":"0","summary":"青城新药生物科技（青岛）股份有限公司10月20日公告称，董事会已委任董事会主席兼执行董事贾丽加女士出任公司首席执行官，自2026年10月20日起生效，其任期至首届董事会任期届满之日结束。贾丽加现年58岁，为青城新药-B创始人，自2012年4月公司成立以来一直担任董事及董事会主席，并于2024年4月起出任执行董事。此外，青城新药-B计划于2026年11月6日（星期五）召开2026年第三次临时股东大会。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02396"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676009695","title":"青城新药-B(02396.HK)：贾丽加获委任为公司首席执行官","url":"https://stock-news.laohu8.com/highlight/detail?id=2676009695","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676009695?lang=zh_cn&edition=full","pubTime":"2026-10-20 20:53","pubTimestamp":1792500788,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02396","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113921253","title":"青城新药-B（02396）宣布更换合规顾问 新百利融资自2026年10月15日上任","url":"https://stock-news.laohu8.com/highlight/detail?id=1113921253","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113921253?lang=zh_cn&edition=full","pubTime":"2026-10-15 16:45","pubTimestamp":1792053934,"startTime":"0","endTime":"0","summary":"青城新药-B10月15日公告称，已与原合规顾问东方融资（香港）有限公司因内部业务评估及商业考量签署终止协议，双方的合规顾问协议自2026年10月15日起终止。公司董事会与东方融资确认，除公告所述事项外，暂无其他需提请股东及香港联交所关注的事宜。本次合规顾问变更不影响公司现有经营与合规工作，董事会已就相关事项作出充分披露与确认。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02396"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675302246","title":"青城新药-B(02396.HK)：新百利获委任为新任合规顾问","url":"https://stock-news.laohu8.com/highlight/detail?id=2675302246","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675302246?lang=zh_cn&edition=full","pubTime":"2026-10-15 16:42","pubTimestamp":1792053721,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02396"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145196982","title":"青城新药-B更新2026年9月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1145196982","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145196982?lang=zh_cn&edition=full","pubTime":"2026-10-07 19:11","pubTimestamp":1791371474,"startTime":"0","endTime":"0","summary":"青城新药生物科技（青岛）股份有限公司于2026年10月7日公告了截至2026年9月30日的证券变动月报表。报告期内，公司注册股本数额合计为人民币117,657,522元，其中包括83,022,145股已上市H股和34,635,377股非上市股份，股本数量与上月末保持一致。在股权激励方面，2026年9月4日召开的公司第二次临时股东大会批准并采纳了2026年H股股份奖励计划，授权限额为11,765,752股H股，占通过当日已发行股份总数的约10%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02396"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102855830","title":"青城新药-B（02396）披露Pro-101-2最新研发进展：拟2027年启动全球Ⅲ期临床，2030年在中国实现商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=1102855830","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102855830?lang=zh_cn&edition=full","pubTime":"2026-10-02 16:38","pubTimestamp":1790930307,"startTime":"0","endTime":"0","summary":"10月2日，青城新药生物科技（青岛）股份有限公司发布补充公告，就核心产品Pro-101-2的研发及商业化时间表作出更新，涉及公司2025年年报及2026年中期报告中的相关信息。按当时进度，拟于中国在2027年第二季度完成Ⅱ期临床，并于2027年第三季度启动Ⅲ期临床，预计2029年第二季度完成Ⅲ期试验。于美国拟在2027年第一季度向FDA提交IND申请以启动Ⅲ期临床；于日本拟在2027年第一季度向PMDA提交CTN申请，并计划在2027年第三季度同步启动中美日Ⅲ期临床。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02396"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176320937","title":"青城新药-B2026年中期财报：营收0.01亿元，同比增长59.1%，净利润-1.22亿元，亏损同比扩大40.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1176320937","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176320937?lang=zh_cn&edition=full","pubTime":"2026-09-14 20:33","pubTimestamp":1789389192,"startTime":"0","endTime":"0","summary":"青城新药-B公布截至2026年6月30日止六个月的财务报告。期内归属于公司主业的营收约为0.01亿元，经调整净利润为-1.22亿元，较上年同期-0.87亿元的水平进一步扩大40.6%。报告期内，研发投入约0.61亿元，较上年同期的0.39亿元增长58.8%。与此同时，行政开支约为0.56亿元，同比上升15.6%，亦主要受员工薪酬支出增长影响。经营现金流方面，报告期内经营活动所用现金流量净额为0.66亿元，对比上年同期的0.34亿元，流出规模进一步加大。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"青城新药-B2026年中期财报：营收0.01亿元，同比增长59.1%，净利润-1.22亿元，亏损同比扩大40.6%","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02396"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103404243","title":"青城新药-B（02396）全部7项议案获股东大会通过","url":"https://stock-news.laohu8.com/highlight/detail?id=1103404243","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103404243?lang=zh_cn&edition=full","pubTime":"2026-09-04 21:41","pubTimestamp":1788529265,"startTime":"0","endTime":"0","summary":"2026年9月4日，青城新药生物科技（青岛）股份有限公司召开2026年第二次临时股东大会。会议就7项议案逐项表决，合共91,953,425股股份出席并投票。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02396"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100355769","title":"青城新药-B 8月股份变动月报：股本维持117,657,522股","url":"https://stock-news.laohu8.com/highlight/detail?id=1100355769","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100355769?lang=zh_cn&edition=full","pubTime":"2026-09-04 17:56","pubTimestamp":1788515760,"startTime":"0","endTime":"0","summary":"青城新药-B于2026年9月4日发布2026年8月股份变动月报表。报告期为2026年8月，本次报告显示公司股本保持稳定。根据公告，截至2026年8月31日，公司注册股本合计为117,657,522股，包含83,022,145股于香港联交所上市的H股，以及34,635,377股非上市股份。公告显示，董事会确认该等股份和证券并无额外变动，各类合规要求均已满足，相关法律及其他监管规定已得到严格遵守。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02396"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159130119","title":"青城新药-B（02396）发布临时股东会通告　9月4日审议未上市股份全流通及股权激励等七项议案","url":"https://stock-news.laohu8.com/highlight/detail?id=1159130119","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159130119?lang=zh_cn&edition=full","pubTime":"2026-08-20 22:05","pubTimestamp":1787234754,"startTime":"0","endTime":"0","summary":"青城新药生物科技（青岛）股份有限公司8月20日公告称，公司将于2026年9月4日（星期五）上午十时在北京市丰台区汽车博物馆东路6号院H座北京盈坤维景酒店二层梅花厅举行2026年第二次临时股东大会。为确定有权出席并投票的股东名册，公司H股股份过户登记册将于2026年9月1日至2026年9月4日暂停办理登记。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02396"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660023238","title":"【生物医药小白投研】第一篇：打破认知盲区，建立底层框架","url":"https://stock-news.laohu8.com/highlight/detail?id=2660023238","media":"港股解码","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660023238?lang=zh_cn&edition=full","pubTime":"2026-08-20 16:30","pubTimestamp":1787214600,"startTime":"0","endTime":"0","summary":"生物医药是A股和港股中最特殊的赛道，没有之一。本篇旨在帮助读者打破固有思维，搭建生物医药投资的底层认知框架，为后续的选择、排雷、交易体系打好基础。康方生物：2025年商业化产品销售收入30.33亿元，同比增长51.48%。目前该公司已有4款产品获批上市。典型案例是2026年ASCO期间，康方生物和信达生物等发布了重磅临床数据，但当日股价表现平平。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzI2MDAzMTQ4OA==&mid=2650513943&idx=1&sn=7cbba7ab46d98a94d953d8e9b60809e2&chksm=f30e7cf71bc535c0c64240524852e4b36187629cca446e9bd382f04ea70a74b68d1ffd38d5ce&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["LU0634319403.HKD","LU2488822045.USD","LU1720050803.USD","09926","01801","LU0880133367.SGD","KURE","LU1226287529.USD","LU0501845795.SGD","LU0140636845.USD","02396","IE0008369823.USD","03692","LU0348783233.USD","LU2097828631.EUR","LU0244354667.USD","LU2097828474.EUR","01093","IE00BPRC5H50.USD","LU0463099449.HKD","LU0561508036.HKD","LU1328277881.USD","LU2039709279.SGD","LU0348767384.USD","LU2778985437.USD","LU2097828805.USD","LU0067412154.USD","LU1226287792.SGD","LU0348735423.USD","IE00B031HY20.USD","LU2097828714.EUR","SG9999004220.SGD","06872","IE00BZ08YS42.EUR","01177","09939","06990","LU0326950275.SGD","LU2097828557.USD","LU2242644610.SGD","LU1951186391.HKD","IE00BZ08YR35.GBP","LU0540923850.HKD","LU2328871848.SGD","IE0008368742.USD","IE00B5MMRT66.SGD","BK1521","LU1152091168.USD","BK1583","LU1226287875.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659144449","title":"青城新药-B(02396.HK)建议采纳股份奖励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2659144449","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659144449?lang=zh_cn&edition=full","pubTime":"2026-08-14 21:17","pubTimestamp":1786713467,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02396"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100283402","title":"华芢生物-B拟设H股股份奖励计划　授出首批约232.96万股奖励股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1100283402","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100283402?lang=zh_cn&edition=full","pubTime":"2026-08-14 21:15","pubTimestamp":1786713348,"startTime":"0","endTime":"0","summary":"华生物-B8月14日公告，董事会已批准建议采纳H股股份奖励计划，但须待股东于2026年9月4日召开的临时股东大会通过后方可生效。该计划属香港联交所《上市规则》第17章所定义的股份计划，将遵守相关规定。以本公告日已发行117,657,522股计算，上限为11,765,752股H股；其中可授予服务提供者的分项上限为上述规模的20%，即2,353,150股H股。为确定临时股东大会的出席及表决资格，公司股东名册将于2026年9月1日至9月4日暂停办理股份过户登记。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02396"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659141128","title":"青城新药-B(02396)拟申请H股全流通","url":"https://stock-news.laohu8.com/highlight/detail?id=2659141128","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659141128?lang=zh_cn&edition=full","pubTime":"2026-08-14 20:48","pubTimestamp":1786711707,"startTime":"0","endTime":"0","summary":"智通财经APP讯，青城新药-B 发布公告，鉴于《指引》，董事会已审议并批准参与股东持有的内资股转换为H股(H股)以及该等H股于联交所主板上市及流通。经取得所有相关批准并遵守所有适用的法律、规则及法规后，21,681,762股内资股将转换为H股，且本公司将向联交所申请该等H股于联交所主板上市及买卖。参与股东已同意授予董事会及其授权人士权力以向中国证监会、联交所及其他相关监管机构申请H股全流通，并负责处理有关H股全流通的事宜。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1480296.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02396"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135950352","title":"华芢生物-B（02396）拟申请未上市股份全流通 合计2,168万股占总股本18.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=1135950352","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135950352?lang=zh_cn&edition=full","pubTime":"2026-08-14 20:40","pubTimestamp":1786711245,"startTime":"0","endTime":"0","summary":"2026年8月14日，华生物-B披露公告称，公司董事会已审议并批准向中国证券监督管理委员会及香港联合交易所有限公司申请，将21,681,762股内资股转换为H股并实现全流通，占公司总股本的18.43%。此次全流通涉及六名参与股东，共计64,105,499股现有股份，占公司总股本54.48%。其中，将转换为H股的具体股数及比例如下：","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02396"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659625145","title":"青城新药-B(02396)发布中期业绩 期内亏损1.22亿元 同比增加40.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659625145","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659625145?lang=zh_cn&edition=full","pubTime":"2026-08-14 19:18","pubTimestamp":1786706310,"startTime":"0","endTime":"0","summary":"智通财经APP讯，青城新药-B(02396)发布截至2026年6月30日止6个月的中期业绩，该集团其他收入及收益人民币99.9万元，同比增加59.08%;母公司拥有人应占亏损1.22亿元，同比增加40.65%;每股基本及摊薄亏损1.04元;拟派中期股息每股0.50港元。公告称，其他收入及收益增长主要是由于于2025年12月的全球发售所得款项净额带动银行存款的利息收入上升。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1480199.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02396"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131304218","title":"华芢生物-B（02396）发布2026年中期业绩：研发投入6,127.4万元 净亏损扩大至1.22亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1131304218","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131304218?lang=zh_cn&edition=full","pubTime":"2026-08-14 19:06","pubTimestamp":1786705603,"startTime":"0","endTime":"0","summary":"2026年8月14日，华生物科技（青岛）股份有限公司公告截至2026年6月30日止六个月的未经审计中期业绩。期内公司继续加大研发投入，核心产品临床进展稳步推进，但亏损幅度有所扩大。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02396"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104519343","title":"华芢生物-B（02396）拟于8月14日召开董事会审议2026年中期业绩及股息","url":"https://stock-news.laohu8.com/highlight/detail?id=1104519343","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104519343?lang=zh_cn&edition=full","pubTime":"2026-08-04 17:47","pubTimestamp":1785836823,"startTime":"0","endTime":"0","summary":"青城新药生物科技（青岛）股份有限公司8月4日公告，公司董事会拟于2026年8月14日（星期五）召开会议，审议并通过截至2026年6月30日止六个月的中期业绩公告，并讨论是否派发中期股息（如有）及处理其他事项。公司提示，香港交易及结算所有限公司及香港联合交易所有限公司对本公告内容概不负责，也未就内容的准确性或完整性作出任何声明，并明确表示概不承担由此产生或因依赖该内容而造成的任何损失。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02396"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167045362","title":"华芢生物-B7月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1167045362","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167045362?lang=zh_cn&edition=full","pubTime":"2026-08-03 21:26","pubTimestamp":1785763591,"startTime":"0","endTime":"0","summary":"华生物-B于2026年8月3日公布2026年7月的股份变动月报。根据公告，截至2026年7月31日，公司注册股本保持在1.18亿元人民币。其中，H股依旧维持83,022,145股数量不变，非上市股份则维持在34,635,377股，两类股份数量均无新增、回购或注销活动。公告显示，当月公司并未产生任何股份增发、回购、转让及换股事宜，也无新授或行使的股份期权及其他激励计划。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02396"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653030732","title":"华芢生物更名“青城新药” 去年亏损2.09亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2653030732","media":"经济参考网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653030732?lang=zh_cn&edition=full","pubTime":"2026-07-21 21:52","pubTimestamp":1784641950,"startTime":"0","endTime":"0","summary":"近日，华芢生物（02396.HK）发布公告称，公司中文名称正式变更为“青城新药生物科技（青岛）股份有限公司”。自7月22日起，股份简称也将由“华芢生物-B”变更为“青城新药-B”，英文名称、英文股份简称以及股票代码保持不变，同时将于8月14日启用新网站域名。该公司解释称，原名未能直观体现创新药属性，且“芢”字属于生僻字，在政务公示、投融资检索等场景中存在识别和录入不便。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607213815938840.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607213815938840.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","02396"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.huarenshengwu.com/en/","stockEarnings":[{"period":"1week","weight":-0.087},{"period":"1month","weight":0.0351},{"period":"3month","weight":0.0186},{"period":"6month","weight":-0.4887},{"period":"1year","weight":-0.8997},{"period":"ytd","weight":-0.7631}],"compareEarnings":[{"period":"1week","weight":-0.001},{"period":"1month","weight":-0.0213},{"period":"3month","weight":-0.0153},{"period":"6month","weight":-0.0754},{"period":"1year","weight":-0.0657},{"period":"ytd","weight":-0.0563}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"华芢生物科技（青岛）股份有限公司是一家主要从事生物制药研发的中国公司。该公司致力于开发疗法，重点是针对有医疗需求及市场机会的适应症开发蛋白质药物。该公司的主攻方向是发现、开发和商业化伤口愈合的疗法，目前为血小板衍生生长因子（PDGF）药物。该公司主要在中国国内市场开展业务。","exchange":"SEHK","name":"青城新药-B","nameEN":"B&K CORP-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"青城新药-B(02396)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供青城新药-B(02396)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"青城新药-B,02396,青城新药-B股票,青城新药-B股票老虎,青城新药-B股票老虎国际,青城新药-B行情,青城新药-B股票行情,青城新药-B股价,青城新药-B股市,青城新药-B股票价格,青城新药-B股票交易,青城新药-B股票购买,青城新药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"青城新药-B(02396)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供青城新药-B(02396)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}